Bio platform company Embrix announced on the 12th that it was finally selected as a new super-gap startup for the '2025 Super-Gap Startup 1000+ Project (DIPS 1000+)' hosted by the Ministry of SMEs and Startups.
Embrix was named in this project in recognition of the technological innovation and commercialization potential of its ‘GRAB antibody platform’ for precise target delivery of mRNA therapeutics. The platform is a technology that binds antibodies to mRNA-loaded lipid nanoparticles (LNPs), and has advantages over existing chemical conjugation methods in terms of production efficiency, uniformity of complexes, and improved safety, the company explained. This technology is expected to be applied in the precision medicine field, such as in vivo CAR-T, gene therapy, and anticancer vaccines in the future.
Embrix also signed a technology transfer agreement with KOSDAQ-listed company Igene last month for the next-generation recombinant botulinum toxin (MBT-002). According to the company, MBT-002 is safer than existing toxins due to its low diffusion and low toxicity, and it is characterized by a fast onset of effect and a long duration.
CEO Jeong Sang-won said, “This project selection and technology transfer agreement are the result of the market’s evaluation of Embrix’s technological prowess,” and “As we have been selected for national research and development projects in succession, such as in vivo CAR-T development and development of treatment for intractable head and neck cancer, we plan to spur the commercialization of precision medical technology.”
You must be logged in to post a comment.